FindTrial
Sign In

SI-B003

DRUG11 trials

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Breast CancerCervical CancerColorectal CancerEsophageal CancerGastric CancerHead and Neck Squamous Cell CarcinomaNasopharyngeal CarcinomaNon-small Cell Lung Cancer

Phase 1

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Active, not recruitingNCT04606472
Sichuan Baili Pharmaceutical Co., Ltd.Solid Tumor
Start: 2020-11-10End: 2025-12-31Updated: 2025-09-26
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingNCT05668858
Sichuan Baili Pharmaceutical Co., Ltd.Squamous Cell Carcinoma of Head and Neck
Start: 2023-02-10End: 2027-12-31Target: 130Updated: 2025-09-26
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
RecruitingNCT05949606
Sichuan Baili Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer
Start: 2023-10-30End: 2027-12-31Target: 160Updated: 2025-09-26

Phase 2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
RecruitingNCT05924841
Sichuan Baili Pharmaceutical Co., Ltd.Small Cell Lung Cancer
Start: 2023-11-10End: 2027-12-31Target: 100Updated: 2025-09-26
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
RecruitingNCT05956587
Sichuan Baili Pharmaceutical Co., Ltd.Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer
Start: 2024-01-29End: 2027-12-31Target: 121Updated: 2025-09-26
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
RecruitingNCT05965856
Sichuan Baili Pharmaceutical Co., Ltd.Solid Tumor, Urothelial Carcinoma
Start: 2023-12-11End: 2027-12-31Target: 52Updated: 2025-09-26
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
RecruitingNCT05990803
Sichuan Baili Pharmaceutical Co., Ltd.Cervical Cancer
Start: 2023-11-06End: 2027-12-31Target: 130Updated: 2025-09-26
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
RecruitingNCT06006169
Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma
Start: 2023-10-20End: 2027-12-31Target: 186Updated: 2025-09-26
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
RecruitingNCT06008054
Sichuan Baili Pharmaceutical Co., Ltd.Colorectal Cancer, Esophageal Cancer, Gastric Cancer
Start: 2023-11-16End: 2027-12-31Target: 376Updated: 2025-09-26
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
RecruitingNCT06042894
Sichuan Baili Pharmaceutical Co., Ltd.Breast Cancer
Start: 2023-12-12End: 2027-12-31Target: 58Updated: 2025-09-26
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingNCT06668961
Sichuan Baili Pharmaceutical Co., Ltd.Head and Neck Squamous Cell Carcinoma
Start: 2024-11-07End: 2026-11-01Target: 60Updated: 2026-01-21

Related Papers

SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.
Journal of Clinical Oncology2023-06-016 citations